Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease
Jerry R. Colca, Philipp E. Scherer
Molecular Metabolism (2021) Vol. 55, pp. 101409-101409
Open Access | Times Cited: 25

Showing 25 citing articles:

Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss
Sjaak Pouwels, Nasser Sakran, Yitka Graham, et al.
BMC Endocrine Disorders (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 516
Post-acute sequelae of COVID-19: A metabolic perspective
Philipp E. Scherer, John P. Kirwan, Clifford J. Rosen
eLife (2022) Vol. 11
Open Access | Times Cited: 75
Adipose tissue macrophages secrete small extracellular vesicles that mediate rosiglitazone-induced insulin sensitization
Theresa V. Rohm, Felipe C.G. Reis, Roi Isaac, et al.
Nature Metabolism (2024) Vol. 6, Iss. 5, pp. 880-898
Closed Access | Times Cited: 8
Effects of nanocurcumin supplementation on metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials
Gofarana Wilar, Cecep Suhandi, Kohji Fukunaga, et al.
Pharmacological Research (2025) Vol. 213, pp. 107641-107641
Open Access
Metabolic dysfunction and insulin sensitizers in acute and chronic disease
Jerry R. Colca, Kyle S. McCommis
Expert Opinion on Investigational Drugs (2025), pp. 1-10
Closed Access
Pioglitazone improves learning and memory in a rat model of cholinergic dysfunction induced by scopolamine, the roles of oxidative stress and neuroinflammation
Arezoo Rajabian, Zahra Kioumarsi Darbandi, Mahdieh Aliyari, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
PPAR-γ Partial Agonists in Disease-Fate Decision with Special Reference to Cancer
Sangeeta Ballav, Bini Biswas, Vishal Kumar Sahu, et al.
Cells (2022) Vol. 11, Iss. 20, pp. 3215-3215
Open Access | Times Cited: 26
Novel thiazolidinedione analog reduces a negative impact on bone and mesenchymal stem cell properties in obese mice compared to classical thiazolidinediones
Andrea Beňová, Michaela Ferenčáková, Kristina Bardová, et al.
Molecular Metabolism (2022) Vol. 65, pp. 101598-101598
Open Access | Times Cited: 24
NLRP3 Inflammasome in Atherosclerosis: Putting Out the Fire of Inflammation
Bo‐Zong Shao, Haiyan Xu, Yicheng Zhao, et al.
Inflammation (2022) Vol. 46, Iss. 1, pp. 35-46
Closed Access | Times Cited: 18
The cellular and molecular targets of natural products against metabolic disorders: a translational approach to reach the bedside
Xiaofei Shen, Hongling Yang, Yang Yang, et al.
MedComm (2024) Vol. 5, Iss. 8
Open Access | Times Cited: 3
Waist-to-Hip Ratio and Inflammatory Parameters Are Associated with Risk of Non-Alcoholic Fatty Liver Disease in Patients with Morbid Obesity
Marta Borges‐Canha, João Sérgio Neves, MARIA TAISSA DA SILVA, et al.
Biomedicines (2022) Vol. 10, Iss. 10, pp. 2416-2416
Open Access | Times Cited: 12
An Egg White-Derived Peptide Enhances Systemic Insulin Sensitivity and Modulates Markers of Non-Alcoholic Fatty Liver Disease in Obese, Insulin Resistant Mice
Stepheny C. de Campos Zani, Ren Wang, Hellen Veida-Silva, et al.
Metabolites (2023) Vol. 13, Iss. 2, pp. 174-174
Open Access | Times Cited: 7
Insulin sensitizers in 2023: lessons learned and new avenues for investigation
Jerry R. Colca, Steven P. Tanis, Rolf F. Kletzien, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 9, pp. 803-811
Closed Access | Times Cited: 6
A dominant negative ADIPOQ mutation in a diabetic family with renal disease, hypoadiponectinemia, and hyperceramidemia
Christopher A. Simeone, Joseph L. Wilkerson, Annelise M. Poss, et al.
npj Genomic Medicine (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 9
Chronic kidney disease combined with metabolic syndrome is a non-negligible risk factor
Lirong Lin, Xianfeng Pan, Yuanjun Feng, et al.
Therapeutic Advances in Endocrinology and Metabolism (2024) Vol. 15
Open Access | Times Cited: 1
Metabolic Mechanisms Connecting Alzheimer’s and Parkinson’s Diseases: Potential Avenues for Novel Therapeutic Approaches
Jerry R. Colca, Brian N. Finck
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 8
Biomarkers of glucose homeostasis as mediators of the relationship of body mass index and waist circumference with COVID-19 outcomes among postmenopausal women: The Women’s Health Initiative
Hind A. Beydoun, Ted Kheng Siang Ng, May A. Beydoun, et al.
Clinical Nutrition (2023) Vol. 42, Iss. 9, pp. 1690-1700
Open Access | Times Cited: 3
Hyperinsulinemia, an overlooked clue and potential way forward in metabolic dysfunction–associated steatotic liver disease
Stephen A. Harrison, Julie Dubourg, M Knott, et al.
Hepatology (2023)
Closed Access | Times Cited: 2
INVESTIGATING THE INTERCONNECTEDNESS BETWEEN METABOLIC ABNORMALITIES AND CARDIOVASCULAR RISKS, AND THE IMPLICATIONS FOR COMPREHENSIVE PATIENT
Sudhair Abbas Bangash, See E., Adut Matik, et al.
(2024), pp. 408-417
Open Access
Pioglitazone alleviates lacrimal gland impairments induced by high-fat diet through suppressing M1 polarization
Yuqing Chen, Y Shao, Rui-Li Wei
Journal of Lipid Research (2024) Vol. 65, Iss. 9, pp. 100606-100606
Closed Access
Insulin resistance has closer correlation with the occurrence of metabolic dysfunction associated steatotic liver disease diagnosed by liver biopsy
Weihua Cao, Tingting Jiang, Wen Deng, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access
Pleiotropic effects of netakimab in patients with psoriatic arthritis, spondylitis and comorbid metabolic syndrome or a new opportunity for weight control? Case report
A. K. Karibova, S. Sh. Akhmedkhanov, M.T. Kudaev, et al.
Terapevticheskii arkhiv (2024) Vol. 96, Iss. 12, pp. 1230-1237
Open Access
Preclinical activities of Cassia tora Linn against aging-related diseases
Sun‐Young Hwang, Chang-Su Na, Byeong Cheol Moon, et al.
Expert Reviews in Molecular Medicine (2022) Vol. 24
Closed Access
Infusions based on medicinal plants and their benefit in metabolic benefit in metabolic syndrome diseases. A systematic review during the years 2016-2021.
Kevin Abel Pizan Cisneros, Orealiz Katherine Cuevas Huamani, Haniel Solís Muñoz, et al.
Proceedings of the 2nd LACCEI International Multiconference on Entrepreneurship, Innovation and Regional Development (LEIRD 2022): “Exponential Technologies and Global Challenges: Moving toward a new culture of entrepreneurship and innovation for sustainable development” (2022)
Open Access
Diversified Program and Targeting Lifestyle Modification among Obese Patients with Non-Alcoholic Fatty Liver Disease
Wafaa Mustafa El Kotb, Naglaa Fawzy Hanafy, Wafaa El Waan, et al.
Deleted Journal (2022) Vol. 13, Iss. 3, pp. 2217-2233
Open Access
Page 1

Scroll to top